Efeitos do uso da suplementação de probióticos na doença hepática gordurosa não alcoólica
Effects of the use of probiotic supplementation in non-alcoholic fatty liver disease
DOI:
https://doi.org/10.34119/bjhrv5n6-128Keywords:
hepatopatia gordurosa não alcoólica, probióticos, suplementação, microbioma intestinalAbstract
Introdução: A doença hepática gordurosa não alcoólica (DHGNA), é uma doença silenciosa e progressiva que cursa com acúmulo de gordura nos hepatócitos em indivíduos abstêmios de álcool, sendo bastante prevalente no mundo, estando associada muitas vezes com doenças cardiovasculares e Diabetes Mellitus. Esta enfermidade apresenta um espectro que varia deste um acúmulo de gordura sem causar inflamação até formação de fibrose e cicatrização, podendo evoluir com cirrose e posterior hepatocarcinoma. Objetivo: avaliar o uso da suplementação de probióticos na esteatose hepática não alcoólica e seu efeito em parâmetros metabólicos, de função hepática e inflamatório. Métodos: o presente estudo consiste em uma revisão sistemática realizada a partir de estudos selecionados das bases de dados PMC, BVS e SciELO. Depois de aplicar os critérios de inclusão e exclusão, se definiram 24 artigos para compor a base de dados deste estudo. Resultados: a suplementação com probióticos demonstrou resultados promissores diminuindo os níveis de enzimas hepáticas, além da melhora do perfil lipídico. As cepas mais utilizadas foram as do gênero Bifidobacterium e Lactobacillus que estiveram ambos presentes em (n=20) 83.3% dos estudos. Conclusão: a Doença hepática gordurosa não alcoólica (DHGNA) tornou-se uma doença de prevalência mundial, o uso de probióticos e simbióticos vem demonstrando resultados positivos nesta doença. Contudo ainda não se tem um consenso sobre o assunto sendo necessário mais pesquisas para suprir essa questão.
References
ABHARI, Khadijeh et al. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clinical nutrition ESPEN, v. 39, p. 53-60, 2020.
AHN, Sang Bong et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Scientific reports, v. 9, n. 1, p. 1-9, 2019.
ALISI, A. et al. Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non‐alcoholic steatohepatitis. Alimentary pharmacology & therapeutics, v. 39, n. 11, p. 1276-1285, 2014.
ANGELICO, F1 et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. The Journal of Clinical Endocrinology & Metabolism, v. 90, n. 3, p. 1578-1582, 2005.
ASGHARIAN, Atefe et al. The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial. International journal of preventive medicine, v. 7, 2016.
BAKHSHIMOGHADDAM, Farnush et al. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. The Journal of Nutrition, v. 148, n. 8, p. 1276-1284, 2018.
BEHROUZ, Vahideh et al. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. Journal of Food Science, v. 85, n. 10, p. 3611-3617, 2020.
CAI, Gen-shen; SU, Hui; ZHANG, Jing. Protective effect of probiotics in patients with non-alcoholic fatty liver disease. Medicine, v. 99, n. 32, 2020.
CAKIR, Murat et al. EFFECT OF SYNBIOTICS IN CHILDREN WITH NON-ALCOHOLIC FATTY LIVER DISEASE. In: Journal of Pediatric Gastroenterology and Nutrition. LWW, 2016. p. S56.
CANI, P. D. et al. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathologie Biologie, v. 56, n. 5, p. 305-309, 2008.
CHALASANI, Naga et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, v. 67, n. 1, p. 328-357, 2018
CHONG, Pui Lin et al. A randomised placebo controlled trial of VSL# 3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC gastroenterology, v. 21, n. 1, p. 1-9, 2021.
DAY, C. P.; SAKSENA, S. Non‐alcoholic steatohepatitis: definitions and pathogenesis. Journal of gastroenterology and hepatology, v. 17, p. S377-S384, 2002.
DUSEJA, Ajay et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): A randomised, double-blind, proof of concept study. BMJ open gastroenterology, v. 6, n. 1, p. e000315, 2019.
EGRESI, Anna et al. Az ökológiai és a konvencionális joghurtfogyasztás lehetséges szerepe a nem alkoholos zsírmájbetegség kezelésében. Orvosi Hetilap, v. 161, n. 35, p. 1466-1474, 2020.
ESLAMPARAST, Tannaz et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. The American journal of clinical nutrition, v. 99, n. 3, p. 535-542, 2014.
FAMOURI, Fatemeh et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. Journal of pediatric gastroenterology and nutrition, v. 64, n. 3, p. 413-417, 2017.
FEROLLA, S. M. Microbiota intestinal e doença gordurosa hepática. Revista Brasileira de Nutrição Funcional, ed. 72, 2017
FEROLLA, Silvia M. et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients, v. 8, n. 7, p. 397, 2016.
IACONO, Anna et al. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. The Journal of nutritional biochemistry, v. 22, n. 8, p. 699-711, 2011
KOBYLIAK, Nazarii et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. 2018.
LANDIS, J. Richard; KOCH, Gary G. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics, p. 363-374, 1977.
LLOPIS, Marta et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, v. 65, n. 5, p. 830-839, 2016
MALAGUARNERA, Michele et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive diseases and sciences, v. 57, n. 2, p. 545-553, 2012.
MANZHALII, Elina et al. Treatment efficacy of a probiotic preparation for non‐alcoholic steatohepatitis: A pilot trial. Journal of digestive diseases, v. 18, n. 12, p. 698-703, 2017.
MIRAGHAJANI, Maryam Sadat et al. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. Diabetes care, v. 35, n. 10, p. 1981-1985, 2012
MOFIDI, Fatemeh et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. British Journal of Nutrition, v. 117, n. 5, p. 662-668, 2017.
MOHAMAD NOR, Mohamad Hizami et al. The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, v. 13, n. 9, p. 3192, 2021.
NABAVI, S. et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. Journal of dairy science, v. 97, n. 12, p. 7386-7393, 2014.
NOBILI, Valerio et al. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. Archives of Medical Science, v. 14, n. 1, p. 81-87, 2018.
SCORLETTI, Eleonora et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology, v. 158, n. 6, p. 1597-1610. e7, 2020.
SEPIDEH, Abbaszadeh et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. Journal of the American College of Nutrition, v. 35, n. 6, p. 500-505, 2016.
VAJRO, Pietro et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. Journal of pediatric gastroenterology and nutrition, v. 52, n. 6, p. 740-743, 2011.
WONG, Vincent Wai-Sun et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of hepatology, v. 12, n. 2, p. 256-262, 2013.
YOUNOSSI, Z. M. Koenig aB, abdelatif D, et al. global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, v. 64, p. 73-84, 2016.
